Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Haematologica. 2024 Jul 1;109(7):2297-2302. doi: 10.3324/haematol.2023.284109.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Bendamustine Hydrochloride* / administration & dosage
  • Bendamustine Hydrochloride* / therapeutic use
  • Female
  • Humans
  • Lymphoma, B-Cell, Marginal Zone* / drug therapy
  • Male
  • Middle Aged
  • Neoplasm, Residual*
  • Rituximab* / administration & dosage
  • Rituximab* / therapeutic use
  • Splenic Neoplasms* / drug therapy
  • Treatment Outcome

Substances

  • Bendamustine Hydrochloride
  • Rituximab

Grants and funding

Funding: This research received an unrestricted contribution from Mundipharma.